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Abstract
Purpose—To understand cultural differences in the impact of cancer (IOC), by (1) performing
an independent psychometric evaluation of the Dutch version of the Impact of Cancer Scale
version 2 (IOCv2) in a non-Hodgkin lymphoma (NHL) sample and (2) examining differences
between Dutch and American NHL survivors in perceived impact of cancer and identify
associations with socio-demographic and clinical characteristics.
Methods—Data collected from 491 Dutch and 738 American NHL survivors were used in this
study. IOCv2 responses were obtained from all survivors; the Dutch survivors also completed the
EORTC QLQ-C30, which measures quality of life.
Results—Exploratory factor analysis of the Dutch version yielded a factor solution similar to the
American structure but with some subscales merging into single factors. Internal consistency was
good; Cronbach's alpha was 0.88 for the Positive and 0.94 for the Negative summary scales. Large
differences were observed between survivors, whereby Dutch survivors reported fewer Positive (Δ
−0.4,p<.001,effect size:0.27) and more Negative (Δ0.2,p≤.001,effect size:0.13) impacts of cancer
independent of socio-demographic and clinical characteristics.
Conclusion—Similar impact domains of the IOCv2 were observed in the Dutch sample,
providing evidence that IOCv2 scales measure common and important survivor concerns across
two different Western nations. Higher positive impacts for US survivors might be explained by
more personal control and availability of supportive services. Future research should focus on
determinants of the impact of cancer in both Dutch and American survivors to gain better
understanding of the factors that might improve it and suggest how health care may be modified
toward that end.
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Advances in cancer treatment have led to an expansion in the number of cancer survivors in
developed countries. Non-Hodgkin's lymphoma (NHL) is one of the diseases that has
benefited from such advances. For both the Netherlands and the United States (US), the
annual age-adjusted incidence of NHL is 1 in 5,000 persons, with approximately 3,000 new
cases in the Netherlands1,2 and 65,000 new cases in the US3 annually. The number of NHL
survivors has increased rapidly from 13,400 in 2001 to 19,600 in 2008 in the Netherlands1,2
and from approximately 347,000 in 2001 to 454,000 in 2008 in the US3. An individual has a
1 in 50 chance of being diagnosed with NHL during his or her lifetime.
As cancer survivors live longer, they develop risks such as late effects of therapy and
adverse physical and psychosocial long-term effects4. These long-term effects include
persistent fatigue, depression, anxiety and marital disruption that can have a negative
influence on survivors' health-related quality of life (HRQOL)5–10. While cancer survivors
may be expected to return to normal life soon after treatment ends, they may continue to be
burdened by the physical and psychosocial effects of the cancer and related treatments.
In a recent systematic review, we found that, on average, lymphoma cancer survivors have
decreased HRQOL compared to the general population even several years post-diagnosis
(i.e., no resolution at more than five years post-diagnosis)11. However, most survivorship
studies lack the use of an instrument that addresses the unique concerns related to the cancer
experience such as those measured by the impact of cancer (IOC) scale12–14. This self-
reported questionnaire was developed in the US to measure positive and negative impacts of
cancer that long-term survivors attribute to their cancer experience. A translation of the IOC
into Dutch has been undertaken, but its psychometric properties have not been described.
Cultural differences may affect the perception of the impact of cancer on HRQOL15,16.
Moreover, attitudes towards health practice and illness may also be defined by culture17.
Therefore, we undertook an examination of two samples of NHL patients in the Netherlands
and the US, and compared their responses to the IOC. To better understand the commonality
of psychosocial problems between cultures, it is important to examine cross-national
differences18. This undertaking will provide more knowledge of culture-specific
determinants of psychosocial well-being.
Therefore, the aims of the present study were to (1) perform an independent psychometric
evaluation of the Dutch version of the IOCv2 in a NHL sample and (2) explore differences
between Dutch and American NHL survivors regarding the impact of cancer and identify




Dutch sample—NHL survivors aged ≥18 were identified using the Eindhoven Cancer
Registry (ECR) to select all patients who were diagnosed with NHL between January 1st,
1999 and July 1st, 2009. We included all patients with indolent (including Chronic
Lymphocytic Leukemia) and aggressive B-cell NHL as defined by the International
Classification of Diseases for Oncology-3 codes (ICD-O-3)19. To identify and exclude
patients who were deceased, the database was linked with the database of the Central Bureau
for Genealogy, which collects data on all deceased Dutch citizens through the civil
municipal registries.
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Data collection took place in summer 2009 and was done within PROFILES (Patient
Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship).
PROFILES is a registry for the study of the physical and psychosocial impact of cancer and
its treatment from a dynamic, growing population-based cohort of both short and long-term
cancer survivors. PROFILES contains a large web-based component and is linked directly to
clinical data from ECR. Details of the data collection method have been previously
described20.
Of the 1026 eligible survivors who were assumed to have received an invitation, 824 (80%)
returned survey materials. Non-respondents were more often diagnosed with indolent NHL
(63% versus 54%, p<.05) and less often diagnosed with stage I disease (19% versus 25%,
p<.05). There were no differences between respondents and non-respondents in gender or
age.
American sample—NHL survivors were identified through Duke University Medical
Center and University of North Carolina at Chapel (UNC) Hill Lineberger tumor registries
in November 2004 as previously described21. Patients were eligible if ≥18 years old at
diagnosis, and ≥2 years post-diagnosis. Prospective participants were mailed a self-
administered survey. Of the 1195 eligible survivors who were assumed to have received an
invitation, 886 (74%) returned survey materials. Participants, compared with non-
participants, were less frequently African American (10% versus 20%, p<.001) and older at
study enrollment (mean age 62.9 versus 58.8 years p<.001).
Total sample—To create more comparable samples, we selected those survivors with
overlapping ICDO-3 codes, i.e. excluding survivors diagnosed with Chronic Lymphocytic
Leukemia in the Dutch sample and survivors with T-cell and NK-cell NHL in the American
sample. We also excluded survivors diagnosed ≤2 years post-diagnosis in the Dutch sample
since the IOC was developed for longer term survivors and the US sample included only this
population13,14. The total sample consisted of 1229 survivors, 491 Dutch and 738 American
survivors (Figure 1). Institutional Review Board approval was obtained in both countries at
all institutions participating in the study and written informed consent was obtained from
each participant.
Measures
The IOC presents statements regarding specific impacts of cancer to which respondents
indicate their level of agreement from 1 (strongly disagree) to 5 (strongly agree). Initial
psychometric scaling of a 81-item IOC questionnaire yielded the 41-item IOC version 1
(IOCv1)13,14. A more recent and comprehensive scaling of the IOC questionnaire yielded
the 37-item IOC version 2 (IOCv2)12. The Dutch survivors completed the IOCv1, which is
missing 7 items that are in IOCv2. A newly developed algorithm was used to impute the 7
missing IOCv2 item scores for the Dutch survivors based on their IOCv1 responses22. The
American survivors completed the 81-item IOC questionnaire and had their responses
scored as IOCv2 scales. Other reports from the American sample have used both the IOCv1
and IOCv2 scoring formats9,10.
The Dutch survivors also completed the Dutch validated version of the European
Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 which assesses
HRQOL in cancer patients23. Response categories range from 1 to 4. After linear
transformation, all scales and single item measures range in score from 0 to 100. A higher
score on function scales and the global health and quality of life scale implies a better
HRQOL, whereas for symptoms (scales and items) a higher score refers to more
symptoms23.
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For both samples, comorbidity was assessed with the Self-administered Comorbidity
Questionnaire (SCQ)24. Marital status and educational level were also assessed in both
samples. For the Dutch sample, clinical information was available from the ECR that
routinely collects data on tumor characteristics, including date of diagnosis, tumor grade,
histology, Ann Arbor stage25, primary treatment, and demographic characteristics, including
gender and date of birth. Clinical data pertaining to the American sample were obtained
from Duke University Medical Center and University of North Carolina at Chapel Hill
Lineberger Tumor Registries and complemented with self-reported data.
Statistical analysis
All statistical analyses were performed using SAS (version 9.1 for Windows; SAS Institute
Inc., Cary, NC). P values of <.05 were considered statistically significant. Differences in
socio-demographic and clinical characteristics between Dutch and American NHL
respondents were assessed using chi-square and t-tests.
Psychometric evaluation—An exploratory factor analysis was conducted on the 37
items of the IOCv2 of the Dutch sample. Factors were extracted using principal components;
the number of factors was selected using eigenvalue >1 and scree plots and promax rotation
were performed. We repeated the factor analysis three times, with six, seven and eight
factors, as the scree plot showed a stabilization point after six and eight factors. Internal
consistency of the IOCv2 of the Dutch sample was measured using Cronbach's alpha. The
Cronbach's alpha coefficient should reach 0.7 or above to be judged as good internal
consistency and reliability26. Concurrent validity was evaluated by calculating Spearman
correlation coefficients between IOCv2 scales and EORTC QLQ-C30 subscales. We
hypothesized that the IOCv2 positive scales would be uncorrelated with the EORTC QLQ-
C30, because they measure distinct constructs. We hypothesized that the IOCv2 negative
scales would be substantially correlated with the EORTC QLQ-C30, because limitations in
functioning and having cancer-related symptoms could have negative impacts on one's
QOL.
Comparison of Dutch and American survivors—The mean IOCv2 scores of the
Dutch NHL survivors were compared with the scores of the American NHL survivors using
independent sample t-tests. Multivariate linear regression analysis was performed to
investigate the independent association between socio-demographic and clinical variables
and IOCv2 scales for the samples (Dutch and American) separately and for the total NHL
sample. Since there were no large differences between countries in associations between




Comparisons between Dutch and American NHL survivors showed significant differences
on most sociodemographic and clinical characteristics (all p<.001) except for age, marital/
partner status and NHL histology (Table 1). Dutch respondents were more often male, had
on average a lower educational level and were less likely to be employed during study
enrollment. Mean interval since diagnosis was shorter among Dutch survivors, who also had
a smaller range of interval (i.e., standard deviation). Dutch survivors also reported fewer
comorbid conditions. Despite statistically significant differences in disease stage and
treatment, both survivor groups were most often diagnosed with stage I disease followed by
stage IV disease, and chemotherapy and radiotherapy were the most common treatments
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received. The mean age at the time of survey for both groups was 63 years and about 80% of
survivors were married or in a committed relationship.
Psychometric evaluation
Exploratory factor analysis—The six factor structure yielded the most interpretable
solution. `Health Awareness and Worry' emerged as a single factor as did `Body Change
Concerns and Life Interferences'. The additional factors represented the four other domains
of the IOCv2, i.e. Meaning of Cancer, Positive Self-Evaluation, Altruism/Empathy, and
Appearance Concerns (Appendix 1). Item IOC29 loaded higher on Meaning of Cancer than
on Health Awareness (0.57 vs. 0.35). The emerging of Body Change Concerns and Life
Interferences as a single domain was also observed in the factor analysis of the American
NHL sample27. Cronbach's alpha was 0.88 for the Positive and 0.94 for the Negative Impact
scales, respectively, and ranged from 0.75 to 0.93 for the subscales.
Concurrent validity—The correlations between IOCv2 Positive scales and the EORTC
QLQ-C30 were all below 0.30, supporting the distinctive content of the IOCv2 Positive
scales from this HRQOL measure (Appendix 2). With respect to IOCv2 Negative scales we
observed an overall pattern of moderate (r≥0.30) to substantial correlation (r≥0.45) with the
EORTC QLQ-C30. The strongest correlation was observed between IOCv2 Body Change
Concerns and Fatigue of the EORTC QLQ-C30 (r=0.61).
Comparison of Dutch and American survivors
Significant differences were observed between Dutch and American NHL survivors on all
IOCv2 scales (all p<.01) except for Meaning of Cancer and Life Interferences (Table 2).
Dutch survivors scored lower on the Positive Impact subscales (i.e., Altruism/Empathy,
Health Awareness and Positive Self-Evaluation) and higher on the Negative Impact
subscales (i.e., Appearance Concerns, Body Change Concerns and Worry). The difference
on the Positive Impact Summary scale was larger compared to the Negative Impact
Summary scale (0.4 vs. 0.2 points, both p<.01).
Multivariate linear regression analysis also showed lower Positive IOCv2 scores and higher
Negative IOCv2 scores (p<.001) for Dutch survivors (Table 3). Based on the total sample of
Dutch and American NHL survivors, females scored significantly higher on several Positive
Impact subscales and on Appearance Concerns. Older survivors scored significantly lower
on both Positive and Negative Impact Summary scales. In addition, higher educated
survivors showed less Altruism/Empathy, survivors without a partner reported more Worry,
and survivors who were not employed or were retired showed less Life Interferences.
With respect to the clinical characteristics, survivors with a longer survival time post-
diagnosis showed higher Positive Self-Evaluation scores, and less Negative Impacts on
Body Change Concerns, and Worry. Survivors with an aggressive NHL histology reported
less Worry. Furthermore, survivors with more advanced disease stage, especially stage IV
disease, showed higher scores on Health Awareness and on all Negative Impact scales.
Survivors treated with chemotherapy reported a higher Positive Self-Evaluation and Positive
Impact Summary scale as well as higher scores on Body Change Concerns. Lastly, survivors
with three or more comorbidities had higher Negative Impact subscale scores.
Discussion
The findings of this study show that similar impact domains were observed for Dutch and
American NHL survivors, providing evidence that the IOCv2 measures common and
important survivor concerns across two different Western nations. The internal reliability
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and consistency of the Dutch scales were good and construct validity was observed between
the IOCv2 negative scales and the EORTC QLQ-C30. Unfortunately, we could not evaluate
the construct validity of the IOCv2 Positive Impact subscales, since the Dutch study did not
have a relevant questionnaire that measured positive growth.
We also observed significant differences between Dutch and American NHL survivors,
whereby Dutch survivors reported less positive impacts and more negative impacts of
cancer. These differences, combined with construct validity, suggest that the IOCv2 scales
are able to distinguish between cultures of the impacts of cancer, and this questionnaire is
thus culturally sensitive.
One explanation for these differences might be that living in different cultures cultivates
other psychological resources which influence health. The structure of a society, such as the
social safety net and health care systems, contributes to shaping population health and
attitudes towards health care28. Individuals in the US are socialized to rely more on
individual resources compared with collective resources in Western Europe16,29. In the US,
health care programs fall under the responsibility of the individual30,31, whereas in the
Netherlands they are administered by the government32,33. To be more responsible for one's
own health care creates a situation wherein control must be exercised. This sense of control
is reflected in the emergence of a patient autonomy movement that began in America during
the 1970s. Since then, a shift was made from a more paternalistic relationship between
physicians and patients to a more equal relationship34,35, whereby information provision is
one of the key elements of patient autonomy36. Studies have shown that personal control is
associated with better self-reported health37,38 since individuals who believe that they have
some degree of control over their lives may be more likely to take action in difficult
situations39. Furthermore, the sense of personal control is more prevalent in North America
than in Europe15, which might result in the ability to alter perceptions of the cancer
experience in a more positive way among American survivors.
Additionally, the hospitals where the American NHL survivors were treated have well-
developed programs in cancer survivorship care. For example, support groups are readily
available and Duke University Medical Center provides free psychosocial counseling and
UNC social workers were available to assist patients free of charge. A recent study reported
that social support is associated with more positive and less negative Impacts of cancer
(Smith et al., under review). Therefore, the higher positive and lower negative impact scores
of the American survivors might be ascribed partly to having received more social support.
Other evaluation of the sample demonstrated that females scored significantly higher on the
positive impacts of cancer (Smith et al., review). However, in the Dutch sample no
differences in impact between men and women were observed, which may reflect other
differences between the genders across the two samples.
Our results related to the impact of cancer are largely consistent with another Dutch study of
562 melanoma survivors40. In both studies, it appeared that time since diagnosis, tumor
stage, and comorbidity were found to be associated with negative impacts of cancer.
The present study had some limitations. Although the response rate was high for both
samples and information was available on socio-demographic and clinical characteristics of
the non-respondents in both samples, it remains unknown whether non-respondents declined
to participate in the study because of poor health. In addition, the seven missing items for
the IOCv2 were calculated with a newly developed algorithm which has not been tested in
other samples yet. Furthermore, the US data were collected from two institutions only,
which limits the heterogeneity of the American sample.
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In spite of these limitations, this study provides important information about the valid use of
the IOCv2 in the Netherlands and with a preliminary look at the cross-national difference of
the IOCv2 between Dutch and American NHL survivors. Results suggest that Dutch NHL
survivors have lower positive and higher negative impacts of cancer compared with their
American counterparts. Higher positive impacts for US survivors might be explained by
more personal control and availability of supportive services. Future research should focus
on determinants of the impact of cancer in both Dutch and American survivors to gain better
understanding of the factors that might improve it.
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Refer to Web version on PubMed Central for supplementary material.
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Flow diagram of the data sample structure.
Note. Flow diagram of the data sample structure, excluding patients with non-similar
International Classification of Diseases for Oncology-3 (ICD-O-3) codes and those
diagnosed less than two years post-diagnosis. CLL=Chronic Lymphocytic Leukemia,
NHL=non-Hodgkin lymphoma, NK=natural killer.
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Table 1
Socio-demographic and clinical characteristics of Dutch and American non-Hodgkin lymphoma survivors.
Dutch Respondents N=491 American Respondents N=738
N (%) N (%) P-value
Gender <.001
 Male 290 (59) 363 (49)
 Female 201 (41) 375 (51)
Age at time of survey: mean (SD) 63.0 (12.5) 63.0 (13.3) .98
 <50 years 71 (15) 111 (15)
 50–64 years 174 (35) 273 (38)
 65+ years 246 (50) 339 (47)
Education 
$ <.001
 Low 111 (23) 81 (11)
 Medium 291 (61) 353 (49)
 High 74 (16) 284 (40)
Marital/partner status .16
 Married/committed 390 (81) 567 (78)
 Not married/committed 92 (19) 164 (22)
Employment status <.001
 Currently employed 116 (25) 287 (42)
 Not employed or retired 339 (75) 400 (58)
Years since diagnosis: mean (SD) 5.3 (2.2) 10.2 (7.3) <.001
 2–4 years 263 (54) 180 (24)
 5–7 years 153 (31) 223 (26)
 8–10 years 75 (15) 151 (17)
 >10 years 0 293 (32)
NHL histology .89
 Indolent 226 (46) 314 (43)
 Aggressive 265 (54) 374 (54)
 Unknown 0 50 (6)
NHL stage at diagnosis .001
 I 153 (31) 183 (28)
 II 93 (19) 149 (18)
 III 75 (15) 133 (17)
 IV 146 (30) 205 (24)
 Unknown
# 24 (5) 68 (13)
Primary treatment/ treatment <.001
 Radiotherapy 148 (30) 363 (49)
 Chemotherapy 343 (70) 618 (84)
 Biologic 0 224 (30)
 Active surveillance
+ 78 (16) 0
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Dutch Respondents N=491 American Respondents N=738
N (%) N (%) P-value
 Transplant* 28 (6) 126 (17)
 Surgery 33 (7) 237 (33)
Self-reported comorbidity <.001
 No comorbid condition 136 (30) 75 (10)
 1 comorbid condition 138 (31) 135 (19)
 2 comorbid conditions 93 (21) 141 (19)
 > 2 comorbid conditions 86 (19) 374 (52)
Note.
$
Education levels included low = no/primary school; medium = lower general secondary education/vocational training; or high = pre-university
education/ high vocational training/university
#
Tumor stage could not be determined in some subtypes of indolent non-Hodgkin Lymphoma.
+
Patients are under active surveillance and receive no therapy.
*
Transplant= autologous stem cell or bone marrow transplantation.
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